BRCA2 Protein

"BRCA2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)

Descriptor ID	D024682
MeSH Number(s)	D12.776.313.249 D12.776.624.776.101 D12.776.660.105
Concept/Terms	BRCA2 Protein BRCA2 Protein FANCD1 Protein Fanconi Anemia Complementation Group D1 Protein Fanconi Anemia Group D1 Protein BRCA2 Gene Product Breast Cancer 2 Gene Product Fanconi Anemia Group D1 Complementing Protein Breast Cancer 2 Protein

Below are MeSH descriptors whose meaning is more general than "BRCA2 Protein".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Fanconi Anemia Complementation Group Proteins [D12.776.313]
BRCA2 Protein [D12.776.313.249]
Neoplasm Proteins [D12.776.624]
Tumor Suppressor Proteins [D12.776.624.776]
BRCA2 Protein [D12.776.624.776.101]
Nuclear Proteins [D12.776.660]
BRCA2 Protein [D12.776.660.105]

Below are MeSH descriptors whose meaning is related to "BRCA2 Protein".

Below are MeSH descriptors whose meaning is more specific than "BRCA2 Protein".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "BRCA2 Protein" by people in this website by year, and whether "BRCA2 Protein" was a major or minor topic of these publications.

Bar chart showing 28 publications over 15 distinct years, with a maximum of 5 publications in 2017 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	0	1	1
2001	0	1	1
2005	0	1	1
2006	1	0	1
2007	1	0	1
2008	0	1	1
2011	1	1	2
2012	0	2	2
2014	1	1	2
2015	1	0	1
2016	2	0	2
2017	4	1	5
2021	1	0	1
2023	0	2	2
2024	2	3	5

Below are the most recent publications written about "BRCA2 Protein" by people in Profiles.

Brody JR, Klein AP. The Pivotal Role of Germline BRCA2 Pathogenic Variants in "Apparently Sporadic" Pancreatic Cancer. Cancer Res. 2024 Sep 16; 84(18):2941-2943.

View in: PubMed
Ito F, Li Z, Minakhin L, Chandramouly G, Tyagi M, Betsch R, Krais JJ, Taberi B, Vekariya U, Calbert M, Skorski T, Johnson N, Chen XS, Pomerantz RT. Structural basis for a Pol? helicase small-molecule inhibitor revealed by cryo-EM. Nat Commun. 2024 Aug 14; 15(1):7003.

View in: PubMed
Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024 Jun; 8:e2300494.

View in: PubMed
Fried W, Tyagi M, Minakhin L, Chandramouly G, Tredinnick T, Ramanjulu M, Auerbacher W, Calbert M, Rusanov T, Hoang T, Borisonnik N, Betsch R, Krais JJ, Wang Y, Vekariya UM, Gordon J, Morton G, Kent T, Skorski T, Johnson N, Childers W, Chen XS, Pomerantz RT. Discovery of a small-molecule inhibitor that traps Pol? on DNA and synergizes with PARP inhibitors. Nat Commun. 2024 Apr 05; 15(1):2862.

View in: PubMed
Bobbili PJ, Ivanova J, Solit DB, Mettu NB, McCall SJ, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq R, Green M, Turski M, Lam P, Muthukumar A, Guo T, Mohan M, Zhang A, Duh MS, Oh WK. Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations. Clin Genitourin Cancer. 2024 Jun; 22(3):102080.

View in: PubMed
Kunwor R, Silver DP, Abu-Khalaf M. PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Hematol Oncol Stem Cell Ther. 2023 Apr 04; 16(3):186-196.

View in: PubMed
Golan T, Raitses-Gurevich M, Beller T, Carroll J, Brody JR. Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors. Cancer Treat Res. 2023; 186:125-142.

View in: PubMed
Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022 02; 126(2):302-309.

View in: PubMed
Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410.

View in: PubMed
Liu J, Kruswick A, Dang H, Tran AD, Kwon SM, Wang XW, Oberdoerffer P. Ubiquitin-specific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth. Nat Commun. 2017 07 26; 8(1):137.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement